Related Experiment Video
Updated: Mar 28, 2026
08:25
Flow Cytometric Characterization of Murine B Cell Development
Published on: January 22, 2021
19.3K
Potential therapeutic targets in plasma cell disorders: A flow cytometry study
Katharina Lisenko1, Stefan Schönland1, Ute Hegenbart1
1Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Cytometry. Part B, Clinical Cytometry
|December 16, 2015
Summary
This study identifies CD20 as a promising therapeutic target in AL-amyloidosis, with high expression observed in 37% of cases. It also suggests assessing SLAMF7 expression before elotuzumab treatment for multiple myeloma.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Targeted therapy discovery is crucial in oncology.
- Antibodies targeting malignant B-cell antigens show clinical benefit.
- Identifying novel targets for plasma cell disorders is essential.
Purpose of the Study:
- To assess antigen expression on malignant plasma cells (PCs) in PC disorders.
- To evaluate CD20, CD22, CD27, CD30, CD38, CD52, CD81, CD138, and SLAMF7 expression.
- To correlate immunophenotyping with cytogenetic data for targeted therapy.
Main Methods:
- Retrospective analysis of 103 PC disorder patients.
- Flow cytometry used for antigen expression detection.
- Cytogenetic data analysis for correlation.
Main Results:
- CD22, CD30, CD52 expression frequencies were consistent with prior studies.
- High CD20 expression (37%) found in AL-amyloidosis cases, correlating with t(11;14).
- Decreased SLAMF7 expression noted in advanced PC disorders and associated with lower CD27/CD81 in multiple myeloma.
Conclusions:
- CD20 emerges as a significant therapeutic target in AL-amyloidosis.
- SLAMF7 expression analysis may predict elotuzumab efficacy in multiple myeloma.
- Findings contribute to advancing targeted therapy options for PC disorders.
